Cingulate (CING) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CING · Stock Price

USD 5.23+1.22 (+30.42%)

Market Cap: $62.0M

Historical price data

Market Cap: $62.0MPipeline: 6 drugs (3 Phase 3)Founded: 2013Employees: 11-50HQ: Kansas City, United States

Sector Ranking#70 in Neuroscience & CNS

Overview

Cingulate is a neuroscience-focused biotech developing treatments for CNS disorders via its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Its strategy is to create single-tablet, multi-release formulations that offer rapid onset and controlled duration of action, primarily targeting unmet needs in ADHD and anxiety. The company's most advanced candidates, CTx-1301 and CTx-1302, are in late-stage development for ADHD, representing its nearest-term value inflection points. As a pre-revenue, publicly traded entity, Cingulate's progress is measured by clinical milestones and its ability to navigate a competitive therapeutic landscape.

NeurosciencePsychiatry

Technology Platform

Proprietary Precision Timed Release™ (PTR™) drug delivery platform designed to create single-tablet, multi-release formulations that provide precise control over the timing and rate of drug release to optimize pharmacokinetic profiles.

Pipeline

6

6 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1...	ADHD	Phase 3
CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylp...	ADHD	Phase 3
CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphe...	ADHD	Phase 3
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release + Dex...	ADHD	Phase 1/2
Dexmethylphenidate	Healthy Volunteers in Fed and Fasted State	Phase 1

Opportunities

Cingulate's primary opportunity is to successfully launch a differentiated ADHD treatment with a precise duration of action, capturing market share in the large and growing non-stimulant segment.

Its PTR™ platform also offers long-term potential to expand into other CNS disorders where timed release is critical, such as anxiety, creating a pipeline-in-a-product opportunity.

Risk Factors

The company faces extreme financial risk due to its pre-revenue status and urgent need for capital, high clinical development risk for its lead assets, and intense commercial competition in the ADHD market.

Failure to secure funding or achieve clearly differentiated clinical results threatens its viability.

Competitive Landscape

Cingulate operates in the highly competitive ADHD market, dominated by large pharma generics and established non-stimulants from companies like Supernus and Eli Lilly. Its success depends entirely on proving its PTR™ platform delivers a clinically superior pharmacokinetic profile that justifies use over cheaper, widely available alternatives.